Literature DB >> 20035333

The effects of PDL-Ig on collagen-induced arthritis.

Guohua Wang1, Ping Hu, Jing Yang, Guanxin Shen, Xiongwen Wu.   

Abstract

Programmed death ligand (PDL) is a new member of the B7 family of costimulatory molecules that specifically interacts with programmed death 1 (PD-1) expressed on activated T cells, B cells, and myeloid cells. Collagen II (CII)-induced arthritis (CIA) is an experimental model of arthritis that has been used to dissect the pathogenesis of human rheumatoid arthritis. In this study, we have investigated the effects of PDL-Ig on CIA. Administration of PDL-Ig significantly ameliorated the disease as assessed by clinical arthritis score and histology in the joints. Expression of proinflammatory cytokines, such as IL-17 and IL-23, in the serum was reduced by PDL-Ig treatment. These results showed a beneficial effect of PDL-Ig on CIA through anti-inflammatory actions and inhibition of cell proliferation in response to CII, suggesting that the PD-1-PDL pathway may be involved in the pathogenesis of CIA, and thus PDL-Ig may be a useful therapy for the improvement of human rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035333     DOI: 10.1007/s00296-009-1249-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

1.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

2.  The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.

Authors:  M Chabaud; P Miossec
Journal:  Arthritis Rheum       Date:  2001-06

3.  Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation.

Authors:  Hideyuki Iwai; Yuko Kozono; Sachiko Hirose; Hisaya Akiba; Hideo Yagita; Ko Okumura; Hitoshi Kohsaka; Nobuyuki Miyasaka; Miyuki Azuma
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

4.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

5.  Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

Authors:  Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Marieke A Hoeve; Matthijs Kramer; Elena Vaisberg; Robert Kastelein; Arend Kolk; René de Waal-Malefyt; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

6.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

7.  Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus.

Authors:  Shih-Chang Lin; Jeng-Hsien Yen; Jaw-Ji Tsai; Wen-Chen Tsai; Tsan-Teng Ou; Hong-Wen Liu; Chung-Jen Chen
Journal:  Arthritis Rheum       Date:  2004-03

8.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

Review 9.  The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.

Authors:  Erik Lubberts; Marije I Koenders; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2004-11-30       Impact factor: 5.156

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  26 in total

1.  The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium.

Authors:  Guoning Guo; Yongjun Shang; Guoyan Zhu; Xiaoren Bao; Shiwei Xu; Yongwen Chen
Journal:  Clin Rheumatol       Date:  2011-07-22       Impact factor: 2.980

2.  Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28.

Authors:  Zohreh Koohini; Hadi Hossein-Nataj; Maryam Mobini; Aref Hosseinian-Amiri; Alireza Rafiei; Hossein Asgarian-Omran
Journal:  Clin Rheumatol       Date:  2018-04-07       Impact factor: 2.980

Review 3.  Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Authors:  Stephanie Grebinoski; Dario Aa Vignali
Journal:  Curr Opin Immunol       Date:  2020-06-30       Impact factor: 7.486

Review 4.  Targeting the programmed cell death-1 pathway in rheumatoid arthritis.

Authors:  Sabina Sandigursky; Gregg J Silverman; Adam Mor
Journal:  Autoimmun Rev       Date:  2017-05-29       Impact factor: 9.754

Review 5.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

Review 6.  Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis.

Authors:  Laura C Cappelli; Mekha A Thomas; Clifton O Bingham; Ami A Shah; Erika Darrah
Journal:  Immunol Rev       Date:  2020-01-13       Impact factor: 12.988

Review 7.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

8.  The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.

Authors:  Yongjun Shang; Guoning Guo; Qifu Cui; Jinlong Li; Zhihua Ruan; Yongwen Chen
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

9.  Program Death-1 Suppresses Autoimmune Arthritis by Inhibiting Th17 Response.

Authors:  Lifen Yang; Guilin Qiao; Yassir Hassan; Zhenping Li; Xiaoqing Zhang; Huimin Kong; Weimin Zeng; Fei Yin; Jian Zhang
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-19       Impact factor: 4.291

Review 10.  Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2021-08-03       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.